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There has long been debate among experts in the care of
infants born with hypoplastic left heart syndrome (HLHS)
as to whether orthotopic heart transplantation or cardiac
reconstruction is preferable as the primary approach [1, 15].
Many centers now favor the reconstructive techniques
(Norwood-type procedure); however, several centers con-
tinue to offer cardiac transplantation as a primary treatment.
By the late 1990s, approximately 50% of children born with
HLHS in the United States underwent cardiac reconstruc-
tion (studies indicate that approximately 35% of infants
born with HLHS in the United States underwent cardiac
reconstruction and survived to hospital discharge [9, 14]
and that the rate of survival to discharge postreconstruction
was approximately 70% [5, 6, 12, 17, 20, 27, 28], yielding a
calculated value of 50% undergoing reconstruction),
approximately 5% underwent cardiac transplantation (with
an additional 2% dying while on the transplant waiting list)
[9, 10, 14], and the remaining patients (approximately 45%)
received palliative treatment (previously referred to as
comfort care without surgery [18]). More recent data have
not been published; therefore, the current percentages
treated with each option is unknown.
In 2007, the American Heart Association Council on
Cardiovascular Disease in the Young, the Councils on
Clinical Cardiology, Cardiovascular Nursing, and Cardio-
vascular Surgery and Anesthesia, and the Quality of Care
and Outcomes Research Interdisciplinary Working Group
issued a consensus statement on indications for heart
transplantation in children [7]. The authors of the consensus
statement noted that improved survival with cardiac
reconstruction and the limited number of available donor
hearts has ‘‘led to a decreased use of heart transplantation as
primary therapy for HLHS’’ [7]; however, the decision
whether to offer transplantation as primary therapy remains
vested with the individual healthcare providers and their
assessment of the best interests of their patient. Although it
appears that most centers currently recommend recon-
struction as the primary approach, a signiﬁcant number
continue to offer parents transplantation as one option for
primary treatment [31]. Therefore, in many cases, infants
with HLHS are treated primarily with cardiac transplanta-
tion based on the providers’ and parents’ beliefs that such
treatment might represent even a slightly better option for
that child over reconstruction. Although such decision
making is consistent with the best interest standard, I will
argue that when viewed from the perspective of the larger
society, where issues of social justice must be considered,
such allocation of a limited resource is inappropriate.
Approximately one-quarter of infants with HLHS who
are listed for heart transplantation die before a heart
becomes available, and the 5-year survival among those
who undergo transplantation is approximately 70% [10].
Based on these ﬁgures, the 5-year survival rate on an
intention-to-treat basis is approximately 50% for trans-
plantation. Further, because the 10-year graft survival is less
than 50% [23, 29], children who undergo heart transplan-
tation will likelyneed another transplant every 10–15 years.
With such a high mortality rate among these and other
children awaiting a donor heart, it is understandable that
healthcare providers continue to look for expanded oppor-
tunities to increase the donor pool (e.g., using hearts from
infants who died from cardiocirculatory causes [4]).
The other predominant surgical approach for these
infants is the three-staged reconstructive technique
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iod, followed by the Glenn procedure at 3–6 months of life,
and, ﬁnally, by the Fontan procedure between 3 and
5 years of age. The 5-year survival for infants whose par-
ents opt for cardiac reconstruction is reported to be
approximately 70% [2, 26], however some predict that the
current survival is even greater than has been reported in
the literature [30].
Regardless of the intervention chosen, survivors often
experience unwanted sequellae. Infants with HLHS are at
risk of abnormal brain development in utero, with
approximately 25% of these infants being born with a head
circumference in the lowest 10th percentile and an addi-
tional 25% having a head circumference in the 10th–20th
percentile [25]. Further, survivors of both procedures are at
risk of neurodevelopmental delay, with mean IQ scores of
86 (SD: 14; range: 57–115) [21]. Approximately 35% of
survivors have borderline mental retardation and an addi-
tional 18% have IQ scores below 70 regardless of surgical
approach [19]. Survivors of both approaches also have
signiﬁcant limitations on their physical activity [13, 22,
24], require multiple admissions to the hospital and repe-
ated procedures that might be frightening and painful for
the child, and experience other negative physical and
emotional effects. Studies comparing outcomes and se-
quellae for infants treated with these two approaches have
demonstrated differences in the types of sequellae; how-
ever, there appears to be no clear beneﬁt of one approach
over the other [16, 21]. Therefore, although some experts
continue to debate which approach is superior, it is clear
that there is no compelling evidence that cardiac trans-
plantation is necessarily superior to cardiac reconstruction.
Unlike newborns with HLHS, some infants have no
other alternative. Children with end-stage cardiomyopathy,
severe noncompaction syndrome, and other terminal heart
defects cannot survive unless they receive a donor heart.
On the whole, infants with HLHS can be equally well
treated with either transplantation or reconstructive sur-
gery; therefore, infants with other diagnoses who have no
reasonable alternative should receive priority over infants
with HLHS for donor hearts. Indeed, there are more than
twice as many infants added to the heart waiting list
annually compared to the number of new donors [7], and
approximately 50 infants die annually while awaiting a
donor heart [11]. Perhaps if society were to use this scarce
resource more wisely, with priority given to non-HLHS
infants and primarily employing cardiac reconstruction for
HLHS, we could reduce the overall number of infants who
die each year. In their recent report, the Denver group
noted that nine infants met donation criteria; however, they
were unable to donate due to lack of an appropriate reci-
pient [4]. These data demonstrate that even if priority were
given to non-HLHS infants, there might be instances in
which a heart is made available to an infant with HLHS for
primary treatment because no other suitable recipient is
identiﬁed. Further, there might be cases when reconstruc-
tive surgery fails, and transplantation becomes the only
reasonable rescue therapy for an infant with HLHS. In such
cases, giving an infant with HLHS equal access to donor
hearts would be reasonable.
The standard used in pediatric decision making is that of
the child’s best interest. Clinicians and parents are charged
with using the best interest standard when making deci-
sions for individual infants, although some have argued
that parents might give some weight to the interests of
other family members [3, 8]. Although data suggest similar
burdens of sequellae for survivors regardless of the treat-
ment employed, the types of sequellae differ signiﬁcantly,
with transplant recipients being at higher risk for hyper-
tension, renal dysfunction, infections, and rejection and
Norwood survivors being at higher risk of requiring anti-
congestive medications and interventional catheterizations
[16]. Further, parents must weigh how other aspects of care
might affect their family (e.g., many transplant centers
require that families who live in remote areas relocate
closer to the facility for a signiﬁcant period of time post-
transplantation). Individual practitioners and centers might
also have biases favoring one approach over the other, and
such biases might lead to greater experience, and therefore
improved outcomes, with one approach. It might therefore
be very appropriate for individual parents to judge that
transplantation is the best option for their child.
Although such an approach to decision making is
appropriate and expected for parents and healthcare pro-
viders, when viewing the healthcare system as a whole one
must also consider issues of social justice. The United
Network for Organ Sharing (UNOS) is charged with allo-
cation of organs, and unlike clinicians caring for individual
patients, UNOS must create policies that consider the
interests of not only individual patients but also the inter-
ests of society as a whole. Therefore, UNOS might create
policies that balance individual and societal interests and
has done so in the past. Given that (1) for one group of
infants (those with HLHS) there is no clear advantage for
employing transplantation as the primary approach, (2) for
another group of infants (e.g., those with end stage car-
diomyopathy) transplantation is the only viable option, and
(3) donor hearts are a scarce resource, the only tenable
alternative is to give priority to infants who cannot be
treated by any means other than transplantation. To be
clear, however, such a decision should only be made on a
broad basis with applicability nationally. UNOS would
need to change policy regarding how organs are allocated.
It would be inappropriate for individual practitioners to
make such decisions independently because to do so would
likely lead to signiﬁcant disparities in healthcare provision
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individual patients.
Such a policy change might initially adversely affect a
small number of infants (e.g., infants born at a transplan-
tation center where the surgeons have little experience
performing the Norwood procedure would likely have a
lower survival rate when compared to the center’s current,
posttransplantation, survival rate); however, as centers gain
experience with the Norwood procedure, such adverse
effects would be signiﬁcantly diminished. With approxi-
mately 50 deaths annually due to lack of available donor
hearts, one would expect that the implementation of a
policy giving priority to non-HLHS infants and encourag-
ing the Norwood procedure as primary life-prolonging
treatment for infants with HLHS would save many lives.
Although the goal of parents and clinicians is, and should
be, acting in the best interest of the individual child, as a
society we must take a wider view.
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